E
BOLT icon

Ergoteles’s Bolt Biotherapeutics BOLT Stock Holding History

Ergoteles’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,425
Closed -$37.1K – 1286
2022
Q4 		$37.1K Sell
1,425
-2,984
-68% -$81.8K ﹤0.01% 1319
2022
Q3 		$130K Sell
4,409
-874
-17% -$36.2K ﹤0.01% 1308
2022
Q2 		$216K Buy
+5,283
New +$205K 0.01% 1282

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ergoteles's BOLT Position: Q1 2023 in Review

Ergoteles sold out of Bolt Biotherapeutics (BOLT) in Q1 2023, closing a stake of 1,425 shares — an estimated $37.1K sold.

Ergoteles first reported a position in BOLT in Q2 2022 and held it in 3 quarters. The position peaked at $216K in Q2 2022. 40 funds tracked by Wall St. Rank hold BOLT as of Q1 2023.

  • Ergoteles reported no remaining Bolt Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 1,425 Bolt Biotherapeutics shares in Q1 2023, an estimated $37.1K.
  • Ergoteles first reported a position in Bolt Biotherapeutics in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Bolt Biotherapeutics position peaked at $216K in Q2 2022.
  • 40 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.